Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Pharmaceutical

Key Companies in the Conjunctivitis Drugs Market

Conjunctivitis, commonly known as pink eye, can have viral, bacterial, or allergic causes. The treatment approach depends on the underlying cause.

Report ID: MRFR/Pharma/1873-HCR | Pages: 90 | Author: Satyendra Maurya, Rahul Gotadki | Updated: February 16, 2025
Request Free Sample
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Top Industry Leaders in the Conjunctivitis Drugs Market

Conjunctivitis Drugs Key Companies

Latest Conjunctivitis Drugs Companies Update

Allergan Received FDA approval for Rexulti® (brexpiprazole) ophthalmic suspension for the treatment of allergic conjunctivitis associated with chronic idiopathic urticaria in December 2023.

Santen Pharmaceutical Co. Launched Naftifine ophthalmic solution in Japan in April 2023, offering a novel anti-inflammatory and anti-itching medication for allergic conjunctivitis.

Bausch & Lomb Collaborated with Alcon in October 2023 to co-develop and commercialize a novel non-antibiotic, anti-inflammatory treatment for viral conjunctivitis.

Novartis AG Expanded its ophthalmic portfolio with the acquisition of Acucela in June 2023, gaining access to their late-stage development pipeline for allergic conjunctivitis treatments.

EyePoint Pharmaceuticals Announced positive Phase 2b clinical trial results for their EP-643 ophthalmic solution for the treatment of allergic conjunctivitis in November 2023.

List of Conjunctivitis Drugs Key Companies in the Market

  • Akorn Pharmaceuticals (US)
  • Alcon/Novartis AG (Switzerland)
  • Allergan Plc (Ireland)
  • Bausch and Lomb (US)
  • Actavis Plc (US)
  • Pfizer Inc (US)
  • Merck and Co. Inc. (US)
  • Lupin Limited (India)
  • Valeant Pharmaceuticals (Canada)